Q1 25 EPS
$1.09
BEAT +1.75%
Est. $1.07
Q1 25 Revenue
$10.36B
MISS 0.57%
Est. $10.42B
vs S&P Since Q1 25
-69.3%
TRAILING MARKET
ABT -32.2% vs S&P +37.1%
Market Reaction
Did ABT Beat Earnings? Q1 2025 Results
Abbott Laboratories posted a mixed but largely encouraging first quarter of 2025, beating Wall Street's profit expectations while falling just short on revenue. Adjusted diluted EPS came in at $1.09, clearing the $1.07 consensus estimate by 1.75%, wh… Read more Abbott Laboratories posted a mixed but largely encouraging first quarter of 2025, beating Wall Street's profit expectations while falling just short on revenue. Adjusted diluted EPS came in at $1.09, clearing the $1.07 consensus estimate by 1.75%, while reported sales of $10.36 billion grew 4.0% year over year but trailed the $10.42 billion consensus by 0.57%. The real engine behind the quarter was Medical Devices, where 9.9% reported sales growth to $4.89 billion was led by FreeStyle Libre continuous glucose monitor sales surging 18.3% to $1.70 billion, helping offset a weak Diagnostics segment dragged down by sharply lower COVID-19 testing revenue. Despite acknowledging tariff headwinds in the hundreds of millions of dollars, a challenge shared across the broader medtech sector, Abbott reaffirmed its full-year guidance for organic sales growth of 7.5% to 8.5% and adjusted diluted EPS of $5.05 to $5.25, with second-quarter adjusted EPS projected at $1.23 to $1.27, signaling management's confidence in its diversified global manufacturing footprint.
Key Takeaways
- • Diabetes Care continuous glucose monitors grew 21.6% organically, reaching $1.7 billion in quarterly sales
- • Medical Devices segment led growth with 12.6% organic sales increase
- • Strong U.S. sales growth of 8.4% on a reported basis
- • Adult Nutrition organic growth of 8.7% driven by Ensure and Glucerna
- • Adjusted gross margin expanded 140 basis points to 57.1%
- • Adjusted operating margin improved 130 basis points to 21.0%
ABT YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
ABT Revenue by Segment
With YoY comparisons, source: SEC Filings
ABT Revenue by Geography
With YoY comparisons, source: SEC Filings
“Once again, Abbott's diversified business model delivered top-tier sales and EPS growth. It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.”
— Robert B. Ford, Q1 2025 Earnings Press Release
ABT Earnings Trends
ABT vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABT EPS Trend
Earnings per share: estimate vs actual
ABT Revenue Trend
Quarterly revenue: estimate vs actual
ABT Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $1.15 | — | $11.16B | +1.51% |
| Q4 25 BEAT FY | $1.49 | $1.50 | +0.67% | $11.46B | -2.94% |
| FY Full Year | $5.17 | $5.15 | -0.42% | $44.33B | -0.78% |
| Q3 25 BEAT | $1.30 | $1.30 | +0.05% | $11.37B | -0.21% |
| Q2 25 BEAT | $1.25 | $1.26 | +0.80% | $11.14B | +1.08% |
| Q1 25 BEAT | $1.07 | $1.09 | +1.75% | $10.36B | -0.57% |